# Shahzad Malik

> Shahzad Malik is a Series B investor at Advent Life Sciences backing Health Care. See 17 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Advent Life Sciences](https://shizune.co/investors/profile/advent-life)
- Location: London, United Kingdom
- Total investments: 17
- Last investment: Jan 2025
- Lead investor: 47%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/shahzad-malik-59b08510/

Shahzad Malik is a Series B investor at Advent Life Sciences in London focused on Health Care and Biotechnology. Shahzad joined Advent in 1999 with a strong background in science, clinical medicine, and international finance.He gained an MA in Physiological Sciences from Oxford University and an MD from Cambridge University, after which he specialised in interventional cardiology while also pursuing clinical and fundamental scientific research in heartmuscle disorders.Since joining Advent, Shahzad has been actively involved with 21 portfolio Companies in Europe and the USA in all sectors of Life Sciences, including Algeta, Respivert, Biocartis and PowderMed.Shahzad currently serves on the Board of several portfolio Companies, including Acutus, Agenus and Versartis.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 6 | 35% |
| Biotechnology | 5 | 29% |
| Medical | 4 | 24% |
| Therapeutics | 3 | 18% |
| Medical Device | 2 | 12% |

18 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 4 | 24% |
| Series C | 4 | 24% |
| Series A | 3 | 18% |
| Series D | 2 | 12% |
| Seed | 1 | 6% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 5 | 29% |
| United Kingdom | 3 | 18% |
| Ireland | 1 | 6% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Relief Cardiovascular | Relief Cardiovascular is an inQB8 medical technologies portfolio company developing a revolutionary smart implant to decongest heart failure patients. | $12M | Series A | Jan 08, 2025 |  |
| Moximed | Moximed Inc. is dedicated to improving the standard of care for patients with osteoarthritis, and is investigating therapies to treat a number of affected joints. The lead product, the KineSpring® Knee Implant System, is designed for patients with knee osteoarthritis. | $61M | Series D | Aug 13, 2024 |  |
| Moximed | Moximed Inc. is dedicated to improving the standard of care for patients with osteoarthritis, and is investigating therapies to treat a number of affected joints. The lead product, the KineSpring® Knee Implant System, is designed for patients with knee osteoarthritis. | $40M | Series C | Aug 16, 2022 |  |
| MiroBio | MiroBio's platform is based on ground-breaking research by their scientific founders at the University of Oxford delineating how immune cells communicate and how they are activated. These insights have enabled MiroBio to create antibodies that can leverage natural signalling mechanisms to restore immune system balance and control. | $97M | Series B | Jun 29, 2022 |  |
| Wondr Medical | Wondr Medical is the platform for medical discovery, built around health care professionals. | $14.6M | Seed | Jun 28, 2022 |  |
| Proximie | Proximie is a health technology platform that enables surgeons to virtually attend operating theaters to visually guide complex surgeries.Proximie combines human expertise with the power of augmented reality, artificial intelligence, and machine learning to allow a surgeon to remotely watch an operation and use their hands to demonstrate thingsto the surgeon conducting the operation, who sees the remote surgeon on a screen. This platform aims to democratize access to the most up-to-date and skilled knowledge on surgery practice, by helping surgeons advise each other from different parts of the world.The company was founded by Nadine Hachach-Haram in 2016 and is headquartered in London, England. | $80M | Series C | Jun 14, 2022 |  |
| MiroBio | MiroBio's platform is based on ground-breaking research by their scientific founders at the University of Oxford delineating how immune cells communicate and how they are activated. These insights have enabled MiroBio to create antibodies that can leverage natural signalling mechanisms to restore immune system balance and control. |  | Series A | Oct 07, 2019 |  |
| Iterum Therapeutics | Iterum Therapeutics is a clinical-stage pharmaceutical company that develops significantly differentiated anti-infectives. It aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum’s first product is a novelanti-infective compound that has demonstrated potent in-vitro activity vs. a wide variety of gram-negative, gram-positive, and anaerobic bacteria resistant to other antibiotics. | $65M | Series B | May 19, 2017 |  |
| Moximed | Moximed Inc. is dedicated to improving the standard of care for patients with osteoarthritis, and is investigating therapies to treat a number of affected joints. The lead product, the KineSpring® Knee Implant System, is designed for patients with knee osteoarthritis. | $50M | Series C | Mar 17, 2017 |  |
| Moximed | Moximed Inc. is dedicated to improving the standard of care for patients with osteoarthritis, and is investigating therapies to treat a number of affected joints. The lead product, the KineSpring® Knee Implant System, is designed for patients with knee osteoarthritis. | $50M | Series C | Mar 16, 2017 |  |

10 of 17 investments shown.

## Co-investors
- [Gilde Healthcare](https://shizune.co/investors/profile/gilde-healthcare-partners) — VC Fund, 5 deals together
- [Future Fund](https://shizune.co/investors/profile/future-fund) — VC Fund, 4 deals together
- [GBS Ventures](https://shizune.co/investors/profile/gbs-ventures) — VC Fund, 4 deals together
- [Index Ventures](https://shizune.co/investors/profile/index-ventures) — VC Fund, 4 deals together
- [Morgenthaler Ventures](https://shizune.co/investors/profile/morgenthaler-ventures) — VC Fund, 4 deals together
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 4 deals together

## About Advent Life Sciences

VC Fund · London, United Kingdom

Advent Life Sciences is a venture team investing in life sciences businesses. The team consists of 11 professionals with extensive scientific, medical and operational experience, and a long-standing track record of entrepreneurial and investment success across the UK, Europe and the US. The Firm invests in a range of sectors within life sciences,principally in new drug discovery, enabling technologies, and med tech. Realizations in the last three years include Algeta, Avila, CN Creative, EUSA, Micromet. Current investments include Acutus, Biocartis, Cellnovo, f2G, NeRRe,

5 contacts available at Advent Life Sciences.

| Name | Title | Profile |
| --- | --- | --- |
| Andrew J Wood | Venture Partner | https://shizune.co/investors/profile/andrew-j-wood |
| Dale Pfost | General Partner | https://shizune.co/investors/profile/dale-pfost |
| Kaasim Mahmood | General Partner | https://shizune.co/investors/profile/kaasim-mahmood |
| Satish Jindal | General Partner | https://shizune.co/investors/profile/satish-jindal |
| Shahzad Malik | General Partner | https://shizune.co/investors/profile/shahzad-malik |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Shahzad Malik invest in?

Shahzad Malik invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series C stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Shahzad Malik last invest?

The most recent investment recorded for Shahzad Malik closed in Jan 2025. Shizune tracks 17 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co